Prurigo nodularis
☆ I le 2022 Stiftung Warentest i'uga mai Siamani, o le fa'amalieina o tagata fa'atau i ModelDerm sa na'o sina maualalo ifo nai lo fa'atalanoaga telemedicine totogi.
References
Prurigo nodularis ose ma'i e tumau pea le pa'u o lo'o fa'aalia i le tele o patupatu ma nodules, e masani ona maua i vaega pito i fafo o lima ma vae. O nei patupatu e mafai ona eseese le lanu mai le tino i le lanu piniki ma e matua mageso lava. E mafai ona afaina ai tagata o soo se matua ma e masani ona fesoʻotaʻi ma isi tulaga o le paʻu e mafua ai le mageso tumau, pei o le atopic dermatitis. O togafitiga e aofia ai vailaʻau malolosi e faʻamaʻi ai le maʻi, vailaʻau e aʻafia ai le puipuiga o le tino, ma vailaʻau e taulaʻi ai le tino. O le puleaina o le prurigo nodularis e masani ona aofia ai togafitiga umi.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Togafitiga e masani ona aofia ai le fa'aaogaina o kulimi po'o tui o vaila'au fa'ama'i i le vaega ua a'afia. I tulaga e sili atu ona ogaoga poʻo le faʻamaʻaʻa, togafitiga e pei o togafitiga mama poʻo vailaʻau e taofia ai le puipuiga o le tino e ono manaʻomia. Thalidomide ma lenalidomide o ni filifiliga mo mataupu ogaoga, ae e mafai ona i ai ni aʻafiaga ogaoga. O togafitiga fou (opioid receptor antagonists, neurokinin-1 receptor antagonists) o lo'o fa'aalia ai le folafolaga i le togafitia o prurigo nodularis ma le itiiti ifo o a'afiaga e fa'atusatusa i le thalidomide po'o le lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Chronic prurigo ose ma'i o le pa'u e fa'ailoa mai ile mageso umi (e silia ma le 6 vaiaso) , manu'a e a'afia ai le pa'u, ma le tala'aga o le sasa soo. E aofia ai le neuroinflammation ma fibrosis i le paʻu.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Prurigo nodularis ose fa'afitauli umi o le pa'u e fa'ailogaina ile mageso. Matou te le iloa tonu le mafuaʻaga, ae e foliga mai o faʻafitauli puipuia ma neura e iai sona sao i le taamilosaga o le mageso. I le taimi nei, e leai ni togafitiga faʻamaonia e le US FDA faʻapitoa mo prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
○ Togafitiga ― OTC Drugs
O le fufuluina o le vaega o manu'a i le fasimoli e le fesoasoani tele ma e mafai ona sili atu ona leaga. OTC steroid ointments e mafai ona fesoasoani e faʻamalolo auga, ae masani ona manaʻomia le faʻaogaina mo ni nai vaiaso e faʻaleleia ai. O le fa'aauauina o le inuina o antihistamines e fesoasoani fo'i e fa'amama ai le mageso.
#OTC steroid ointment
#OTC antihistamine
○ Togafiti
#Intralesional triamcinolone injection